Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Gynecology

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 101 articles: HTML format

Single Articles

June 2026
1. TORMANEN H, Huhtamaki H, Holster T, Puistola U, et al
   Prior Chlamydia trachomatis Infection and the Risk of Epithelial Ovarian Cancer and Borderline Ovarian Tumors.
   Anticancer Res. 2026;46:3257-3265.
   PubMed     Abstract available
   
   
   
2. SEKSAF NA, Roberts HL, Lewis ME, Smits A, et al
   Quality of Life Outcomes Following Pelvic Exenteration for Gynaecological Malignancies: A Systematic Review.
   Anticancer Res. 2026;46:2945-2963.
   PubMed     Abstract available
   
   
   
3. MORGENSTERN B, Schmidt M, Thangarajah F
   Dual Modality and Site-differentiated Sentinel Node Mapping in Vulvar Cancer.
   Anticancer Res. 2026;46:3417-3423.
   PubMed     Abstract available
   
   
   May 2026
4. SALIMIAGHDAM N, Yang X, Liang H
   The Ovarian Portal: An Unusual Pathway to Discovery, A Rare Initial Manifestation of Colon Cancer.
   Anticancer Res. 2026;46:2915-2923.
   PubMed     Abstract available
   
   
   
5. BIEGANSKA O, Biczak E, Przywara G, Blok R, et al
   Ovarian Sertoli Cell Tumor Coexisting With Uterine Malformation: A Case Report.
   Anticancer Res. 2026;46:2925-2936.
   PubMed     Abstract available
   
   
   
6. CHANG WS, Tsai CW, Chen JC, Wang YC, et al
   Inflammatory Cytokine Genotypic Markers and Ovarian Cancer Risk.
   Anticancer Res. 2026;46:2863-2876.
   PubMed     Abstract available
   
   
   
7. HOGDALL EV, Vestergaard LK, Oliveira DNP, Poulsen TS, et al
   Ascites: A Potential Diagnostic Surrogate for Genetic Profiling in Ovarian Cancer.
   Anticancer Res. 2026;46:2899-2913.
   PubMed     Abstract available
   
   
   
8. OZAWA Y, Tanigawa H, Fujimiya T, Abe Y, et al
   Risk Factors for Niraparib-induced Severe Anemia in Japanese Patients With Ovarian Cancer: A Multicenter Study.
   Anticancer Res. 2026;46:2887-2897.
   PubMed     Abstract available
   
   
   
9. TANISKIDI A, Giannas E, Lekka S, Taniskidi A, et al
   Recurrence and Malignant Transformation After Borderline Ovarian Tumors: A Systematic Review and Meta-analysis.
   Anticancer Res. 2026;46:2831-2849.
   PubMed     Abstract available
   
   
   
10. MIYATA K, Yotsumoto F
    Metabolism-driven Immune Escape Defines Therapeutic Vulnerability in Type I and Type II Ovarian Cancer.
    Anticancer Res. 2026;46:2851-2861.
    PubMed     Abstract available
    
    
    
11. AVSAR H, Eroglu I, Demirci A, Gonul II, et al
    Ovarian Metastasis from EBV-Associated Undifferentiated Nasopharyngeal Carcinoma: An Exceptionally Rare Occurrence.
    Anticancer Res. 2026;46:2937-2943.
    PubMed     Abstract available
    
    
    
12. DAWOOD M, Ooko E, Efferth T, Boulos JC, et al
    Prognostic Relevance of FOS and JUN Family Members and Immune Cell Infiltration for the Survival of Patients With Ovarian Carcinoma.
    Anticancer Res. 2026;46:2877-2886.
    PubMed     Abstract available
    
    
    
13. PLATSOUCAS CD
    Ovarian Carcer Immunology and Immunotherapy: Editorial Note.
    Anticancer Res. 2026;46:2829.
    PubMed    
    
    
    April 2026
14. SARKAR S, Saha A, DAS B, DAS D, et al
    Phosphodiesterase 5 Inhibitor Sildenafil Inhibits HPV(+) Cervical Cancer Cells and Cervical Cancer Stem Cells by Apoptotic Induction and Telomerase Activity Modulation.
    Anticancer Res. 2026;46:2007-2024.
    PubMed     Abstract available
    
    
    
15. MICHA JP, Bohart R, Goldstein BH
    The Impact of Exercise and Diet on Ovarian Cancer Mortality.
    Anticancer Res. 2026;46:1763-1768.
    PubMed     Abstract available
    
    
    
16. PARKER JM, Williams LR, Haines NA, Mayberry TG, et al
    Unveiling the Molecular Blueprint of Spinach Induced Anti-proliferation and Pro-apoptosis in Cervical Cancer.
    Anticancer Res. 2026;46:1833-1841.
    PubMed     Abstract available
    
    
    
17. HELMS L, Sabiani L, Djemouai S, Rambeaud C, et al
    Impact of Biopsy Diagnostic Methods on the Prognosis of Stage I Endometrioid Cancer.
    Anticancer Res. 2026;46:2105-2114.
    PubMed     Abstract available
    
    
    March 2026
18. TONOMURA N, Yoshida K, Morita H, Nakai M, et al
    Diuretic Administration for Vomiting During Concurrent Chemoradiotherapy for Cervical Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2026;46:1497-1506.
    PubMed     Abstract available
    
    
    
19. MASUMOTO S, Tanaka M, Yamamoto K, Hori Y, et al
    HPV18-positive Small Cell Neuroendocrine Carcinoma of the Uterine Cervix Treated With Immunotherapy: A Case Report.
    Anticancer Res. 2026;46:1733-1739.
    PubMed     Abstract available
    
    
    
20. ONISHI T, Niimi H, Kumazaki A, Masaki Y, et al
    EZH2 Expression Is Associated With Sensitivity to Inhibitors and Promotes Malignancy in Endometrial Cancer Cells.
    Anticancer Res. 2026;46:1259-1269.
    PubMed     Abstract available
    
    
    
21. MICHA JP, Bohart RD, Gorman JP, Goldstein BH, et al
    Primary Debulking Surgery Versus Interval Debulking Surgery in the Management of Advanced-Stage Ovarian Cancer.
    Anticancer Res. 2026;46:1175-1182.
    PubMed     Abstract available
    
    
    
22. DIEDRICH D, Silva EF, Willig JB, Ruaro TC, et al
    The Privileged Scaffold Quinoline in Derivatives With Anticancer Potential Mediated by Late Apoptosis.
    Anticancer Res. 2026;46:1475-1487.
    PubMed     Abstract available
    
    
    
23. TSUJI M, Kobayashi K, Kawakami K, Fukuda N, et al
    Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib Therapy.
    Anticancer Res. 2026;46:1651-1659.
    PubMed     Abstract available
    
    
    February 2026
24. FUCINA S, Lerda L, Bartoletti M, Perin A, et al
    Postmenopausal Stage IV Ovarian Yolk Sac Tumor With Neuroendocrine Features: Report of a Rare Case.
    Anticancer Res. 2026;46:1167-1172.
    PubMed     Abstract available
    
    
    
25. NISCO A, Tolomeo M, Sposato A, Paleni D, et al
    Alteration of Flavin Homeostasis in Uterine Cancer.
    Anticancer Res. 2026;46:681-688.
    PubMed     Abstract available
    
    
    
26. SAGER G, Livik M, Hellevik T, Orbo A, et al
    Extracellular cGMP Levels Predict the Response of C4-1 Cervical Cancer Cells to Ionizing Radiation.
    Anticancer Res. 2026;46:611-618.
    PubMed     Abstract available
    
    
    
27. CHECK JH, Check DL, Ganpo-Nkewnkwa N
    Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone.
    Anticancer Res. 2026;46:1153-1165.
    PubMed     Abstract available
    
    
    January 2026
28. HOSHINO N, Yoshida K, Kanemitsu Y, Toyama A, et al
    Individualized Estimated Glomerular Filtration Rate-based Renal Function Association With Cisplatin Treatment Completion in Cervical Cancer.
    Anticancer Res. 2026;46:273-281.
    PubMed     Abstract available
    
    
    
29. EGGER E, Forster S, Adloff L, Marinova M, et al
    Paucimannosylation Is a Prognostic Marker in High-grade Serous Ovarian Cancer.
    Anticancer Res. 2026;46:85-94.
    PubMed     Abstract available
    
    
    December 2025
30. NAKAO T, Harano K, Wakabayashi M, Taki T, et al
    Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma.
    Anticancer Res. 2025;45:5543-5555.
    PubMed     Abstract available
    
    
    
31. NAYAB M, Elnaggar M, Asher V, Bali A, et al
    Comparative Analysis of FDG-PET Versus CT/MRI in Staging and Management of Advanced-stage Cervical Cancer.
    Anticancer Res. 2025;45:5503-5511.
    PubMed     Abstract available
    
    
    
32. TAKATORI E, Shoji T, Jo A, Musashi M, et al
    Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study.
    Anticancer Res. 2025;45:5773-5783.
    PubMed     Abstract available
    
    
    
33. SCHULTZ A, Peters F, Jobst N, Gebauer G, et al
    Impact of the Introduction of the S3 Guideline on the Management of Primary Endometrial Cancer: A Comparative Analysis of Cancer Registry Data from Hamburg (2014-2022).
    Anticancer Res. 2025;45:5533-5542.
    PubMed     Abstract available
    
    
    
34. CHATTERJEE R, Cocking A, Eddama M, Kolomainen D, et al
    Surgical and Oncologic Outcomes in Uterine Carcinosarcoma: A Retrospective Cohort Analysis.
    Anticancer Res. 2025;45:5523-5531.
    PubMed     Abstract available
    
    
    
35. DAO THL, Nakamura K, Okamoto K, Vu TH, et al
    Leucine-rich Repeat-containing 15 as a Potential Marker and Therapeutic Target in Cervical Cancer.
    Anticancer Res. 2025;45:5409-5421.
    PubMed     Abstract available
    
    
    
36. ASANO Y, Sato T, Hozumi C, Han Q, et al
    FDG- and MET-PET Imaging Reveal Glucose and Methionine Addiction in a Primary Endometrial Cancer and Methionine Addiction only in a Para-aortic Lymph-node Metastasis in a 58-year-old Patient.
    Anticancer Res. 2025;45:5819-5824.
    PubMed     Abstract available
    
    
    
37. CHECK JH, Check DL, Wilson C
    Good Quality 66.7% 5-year Overall Survival in Terminal Lung Cancer Patients Treated With Mifepristone.
    Anticancer Res. 2025;45:5785-5798.
    PubMed     Abstract available
    
    
    November 2025
38. ITO Y, Nakamura K, Nakagawa-Saito Y, Suzuki S, et al
    The MDM4 Inhibitor CEP-1347 Activates Wild-type p53 in Ovarian Clear Cell Carcinoma Cells and Potently Inhibits their Growth.
    Anticancer Res. 2025;45:4881-4890.
    PubMed     Abstract available
    
    
    
39. YOO SS, Banish K, Fahmi A, Glasener C, et al
    Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice.
    Anticancer Res. 2025;45:4697-4715.
    PubMed     Abstract available
    
    
    
40. ITO Y, Nakamura K, Nakagawa-Saito Y, Takenouchi S, et al
    Senolytic Elimination of Senescent Ovarian Clear Cell Carcinoma Cells Induced by CEP-1347 With the BH3 Mimetic Navitoclax.
    Anticancer Res. 2025;45:4841-4851.
    PubMed     Abstract available
    
    
    
41. DELL'ATTI L
    Management of Bladder Cancer During Pregnancy: A Narrative Review.
    Anticancer Res. 2025;45:4689-4695.
    PubMed     Abstract available
    
    
    October 2025
42. BARAT S, Ahmadi N, Wijayawardana R, Liauw W, et al
    Survival Outcomes Post-secondary Cytoreduction in Peritoneal Metastatic Cases from Ovarian Cancer: A Single Institute Study.
    Anticancer Res. 2025;45:4281-4293.
    PubMed     Abstract available
    
    
    
43. HIKINO K, Komatsu H, Kazuki Y, Kazuki K, et al
    Matrix Metalloproteinase-1 as an Independent Prognostic Biomarker in Epithelial Ovarian Carcinoma.
    Anticancer Res. 2025;45:4473-4481.
    PubMed     Abstract available
    
    
    September 2025
44. PARK SJ, Koh JW, Lee TB, Han SI, et al
    Biological Role of Replication Factor C Subunit 4 in Cervical Cancer Cell Progression.
    Anticancer Res. 2025;45:3701-3710.
    PubMed     Abstract available
    
    
    
45. FURUKAWA S, Soeda S, Endo H, Yoshimoto Y, et al
    Multidisciplinary Therapy of Uterine Ewing's Sarcoma With the Preservation of Uterus and Ovarian Function by Laparoscopy: A Case Report and Literature Review.
    Anticancer Res. 2025;45:4027-4035.
    PubMed     Abstract available
    
    
    August 2025
46. MUKOHYAMA J, Saito I, Mochizuki S, Ota Y, et al
    Endometrial Cancer Metastatic to the Sigmoid Colon and Pelvic Retroperitoneal Space: A Case Report.
    Anticancer Res. 2025;45:3567-3573.
    PubMed     Abstract available
    
    
    
47. AKAZAWA M, Hashimoto K, Nagano H
    Development and External Validation of Machine Learning-based Models for Predicting Survival Outcomes in Endometrial Cancer: A Population-based Study.
    Anticancer Res. 2025;45:3543-3551.
    PubMed     Abstract available
    
    
    
48. KIYOSHIMA C, Urushiyama D, Yoshikawa K, Ishida K, et al
    microRNA in Chorioamnionitis: Emerging Biomarkers for Early Diagnosis.
    Anticancer Res. 2025;45:3587-3594.
    PubMed     Abstract available
    
    
    July 2025
49. LI M, Yan J, Wei S, Zhao S, et al
    Macranthoside B Enhances Paclitaxel-induced Human Cervical Cancer Cell Apoptosis Through ROS-JNK Pathway.
    Anticancer Res. 2025;45:2859-2870.
    PubMed     Abstract available
    
    
    
50. MICHA JP, Bohart RD, Gorman JP, Goldstein BH, et al
    Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma.
    Anticancer Res. 2025;45:2711-2717.
    PubMed     Abstract available
    
    
    
51. CRISPO A, Luongo A, Nocerino D, Cascella M, et al
    Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study.
    Anticancer Res. 2025;45:3149-3164.
    PubMed     Abstract available
    
    
    May 2025
52. WEHBE S, Gallwas J, Grundker C
    Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Reduces Aggressiveness of Cervical Carcinoma Cells.
    Anticancer Res. 2025;45:1793-1805.
    PubMed     Abstract available
    
    
    
53. BAL J, Fulawka L, Gabrys M, Murawski M, et al
    Potential Role of PTEN and AKT/PKB Proteins in the Pathogenesis of Ovarian Mature Teratomas.
    Anticancer Res. 2025;45:1843-1851.
    PubMed     Abstract available
    
    
    
54. SIMONETTI E, Pistolesi S, Ferrari A, Della Rosa M, et al
    Role of Stromal CD25+/CD8+ Lymphocyte Ratio in Patients With Grade 2-3 Cervical Intraepithelial Neoplasia (CIN 2-3): A Retrospective Single-center Study.
    Anticancer Res. 2025;45:2041-2050.
    PubMed     Abstract available
    
    
    
55. TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al
    Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer.
    Anticancer Res. 2025;45:2071-2078.
    PubMed     Abstract available
    
    
    April 2025
56. DAMPALI R, Nikolettos K, Psilopatis I, Kostaki EG, et al
    The Impact of Body Mass Index on Sentinel Lymph Node Identification in Endometrial Cancer.
    Anticancer Res. 2025;45:1575-1581.
    PubMed     Abstract available
    
    
    March 2025
57. WU YC, Ku MH, Huang WL, Dias L, et al
    NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.
    Anticancer Res. 2025;45:825-842.
    PubMed     Abstract available
    
    
    
58. AHMADU T, Olawade DB, Teke J, Bachour ME, et al
    Diagnosis and Treatment of Gestational Non-Epithelial Ovarian Cancer: A Systematic Review.
    Anticancer Res. 2025;45:843-853.
    PubMed     Abstract available
    
    
    
59. KOH JW, Park SJ
    Knockdown of RFC2 Prevents the Proliferation, Migration and Invasion of Cervical Cancer Cells.
    Anticancer Res. 2025;45:989-1000.
    PubMed     Abstract available
    
    
    February 2025
60. STUEBS FA, Dietl AK, Schulmeyer CE, Behrens AS, et al
    Prognostic Significance of the Detection of Human Papilloma Virus L1 Protein in Smears of Cervical Intraepithelial Neoplasia Grade 3 in Pregnant Women.
    Anticancer Res. 2025;45:677-683.
    PubMed     Abstract available
    
    
    
61. SANTANA BN, Arencibia O, Babin G, Tommasetti E, et al
    Use of Indocyanine Green Fluorescence Angiography to Assess Bowel Anastomosis in Ovarian Cancer Surgery.
    Anticancer Res. 2025;45:661-666.
    PubMed     Abstract available
    
    
    
62. SHIEH PC, Shih HY, Chuang CL, Tsai CW, et al
    Association of Matrix Metalloproteinase-1 Promoter Genotypes With Endometriosis Risk.
    Anticancer Res. 2025;45:465-471.
    PubMed     Abstract available
    
    
    January 2025
63. TALIJANOVIC M, Lopacinska-Jorgensen J, Hogdall EV
    Gene Expression Profiles in Ovarian Cancer Tissues as a Potential Tool to Predict Platinum-based Chemotherapy Resistance.
    Anticancer Res. 2025;45:11-26.
    PubMed     Abstract available
    
    
    
64. KARSTENSEN S, Kaiser K, Poulsen TS, Jochumsen K, et al
    Ovarian Adult Granulosa Cell Tumors: A Scoping Review of DNA Alterations and Their Known Significance.
    Anticancer Res. 2025;45:1-10.
    PubMed     Abstract available
    
    
    
65. LINDQVIST PG, Gissler M
    Improved Vitamin D Status Is Associated With Lower Incidence of Stillbirth.
    Anticancer Res. 2025;45:243-250.
    PubMed     Abstract available
    
    
    December 2024
66. KONTOMANOLIS E, Koutras A, Mitrakas AG, Trypsianis G, et al
    Tissue Expression and Plasma Soluble PD-L1 Levels in Patients With Endometrial Cancer.
    Anticancer Res. 2024;44:5525-5530.
    PubMed     Abstract available
    
    
    
67. ULKER EB, Aktas EC, Seyhan MF, Isbir T, et al
    Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells.
    Anticancer Res. 2024;44:5351-5359.
    PubMed     Abstract available
    
    
    
68. CHO Y, Kim HS
    Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.
    Anticancer Res. 2024;44:5515-5524.
    PubMed     Abstract available
    
    
    November 2024
69. LENZ C, Gesemann L, Al-Baldawi Y, Pusken M, et al
    Accuracy of Preoperative Magnet Resonance Imaging to Predict Pathologic T-Stage in Patients With Cervical Cancer.
    Anticancer Res. 2024;44:5081-5085.
    PubMed     Abstract available
    
    
    
70. NA JM, Kim HS
    Comprehensive Clinicopathological and Immunohistochemical Analysis of Human Papillomavirus-independent Squamous Cell Carcinoma and Adenosquamous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2024;44:4969-4981.
    PubMed     Abstract available
    
    
    
71. COCCHI S, Lopacinska-Jorgensen J, Hogdall EV
    Potential Transcriptomic Biomarkers for Predicting Platinum-based Chemotherapy Resistance in Patients With High-grade Serous Ovarian Cancer.
    Anticancer Res. 2024;44:4691-4707.
    PubMed     Abstract available
    
    
    
72. LEE HM, Cho HJ, Lee YM, Kim HJ, et al
    Fostamatinib Inhibits the Proliferation of Ovarian Cancer Cells Through Apoptosis Induction.
    Anticancer Res. 2024;44:4895-4903.
    PubMed     Abstract available
    
    
    
73. SIN J, Kiosea M, Mahdavi K, Akbarpour F, et al
    Investigation of the Efficacy of Nowarta110 in the Treatment of HPV-16 and HPV-18 Oncogenically-transformed Human Cells and Cancer-implanted Animal Models.
    Anticancer Res. 2024;44:4723-4728.
    PubMed     Abstract available
    
    
    
74. LEE J, Chi SA, Choi S, Kim HS, et al
    Invasive Stratified Mucin-producing Carcinoma of the Uterine Cervix: Comparison of Its Clinicopathological Characteristics and Programmed Death-ligand 1 Expression Status With Those of Other Endocervical Adenocarcinomas.
    Anticancer Res. 2024;44:5007-5022.
    PubMed     Abstract available
    
    
    October 2024
75. SANTANA BN, Guyon F, Arencibia O, Babin G, et al
    Factors Limiting Ostomy Reversal After Cytoreductive Surgery for Ovarian Cancer: A Retrospective Study.
    Anticancer Res. 2024;44:4413-4418.
    PubMed     Abstract available
    
    
    
76. LEE J, Heo K
    Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth.
    Anticancer Res. 2024;44:4301-4307.
    PubMed     Abstract available
    
    
    
77. HA H, Ryu JY, Yoon S, Cho YJ, et al
    Anticancer Effects of BAF312 (Siponimod) in Epithelial Ovarian Cancer.
    Anticancer Res. 2024;44:4273-4282.
    PubMed     Abstract available
    
    
    September 2024
78. SMOLARZ B, Lukasiewicz H, Samulak D, Kolacinski R, et al
    Hypoxia-induced Factor-1alpha and its Role in Endometrial Cancer.
    Anticancer Res. 2024;44:3697-3712.
    PubMed     Abstract available
    
    
    August 2024
79. KYRIAZOGLOU A, Papachristou DJ, Moutafi M, Papakosta A, et al
    Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:3331-3336.
    PubMed     Abstract available
    
    
    
80. HIRAKAWA T, Yotsumoto F, Imi S, Ito N, et al
    Adipose-derived Mesenchymal Stem Cell Transplantation Improves Ovarian Function and Oocyte Quality in Aged Mice.
    Anticancer Res. 2024;44:3577-3586.
    PubMed     Abstract available
    
    
    July 2024
81. LI Q, Guan T, Mao J, King BP, et al
    Mast Cell-related Prognosis Signature Characterizes Immune Landscape and Predicts Prognosis of Ovarian Cancer.
    Anticancer Res. 2024;44:2775-2786.
    PubMed     Abstract available
    
    
    
82. CHIEN HJ, Wang YC, Chang WS, Hsieh YH, et al
    Contribution of Matrix Metalloproteinase-7 Genotypes to Endometriosis Risk in Taiwan.
    Anticancer Res. 2024;44:3051-3058.
    PubMed     Abstract available
    
    
    
83. CHOI EY, Han EJ, Jeon SJ, Lee SW, et al
    Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy via Inactivation of the PI3K/AKT/mTOR Signaling Pathway.
    Anticancer Res. 2024;44:2961-2972.
    PubMed     Abstract available
    
    
    
84. MAFUNE S, Someya M, Hasegawa T, Tsuchiya T, et al
    Analysis of Treatment Response With Proteins Related to Tumor Immunity in Postoperative Irradiated Cervical Cancer Patients.
    Anticancer Res. 2024;44:3077-3086.
    PubMed     Abstract available
    
    
    
85. ZHANG Y, Niu X, Wang Y, Bao S, et al
    SIRT4 Has an Anti-Cancer Role in Cervical Cancer by Inhibiting Glutamine Metabolism via the MEK/ERK/C-Myc Axis.
    Anticancer Res. 2024;44:2861-2870.
    PubMed     Abstract available
    
    
    June 2024
86. LEONHARDI J, Horn LC, Aktas B, Denecke T, et al
    MRI Texture Analysis of Inguinal Lymph Node Metastasis in Vulvar Cancer - Associations With Histopathology.
    Anticancer Res. 2024;44:2709-2716.
    PubMed     Abstract available
    
    
    
87. MORGENSTERN B, Thangarajah F, Schmidt M, Lenz C, et al
    Clinical Impact of Pelvic Sentinel Lymph Node Biopsy for Vulvar Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2621-2626.
    PubMed     Abstract available
    
    
    
88. KITSOS-KALYVIANAKIS K, Pitsikakis K, Mamalis ME, Kalampokis E, et al
    Continuity Unveiled: Evaluating Cytoreduction Outcomes for Advanced Ovarian Cancer Amidst the COVID-19 Era at an ESGO Designated Centre of Excellence.
    Anticancer Res. 2024;44:2645-2652.
    PubMed     Abstract available
    
    
    May 2024
89. YAMAOKA Y, Tamura S, Yamanoi K, Taki M, et al
    Clinical Significance of Serum SCC Levels Before Treatment for Locally Advanced Cervical Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2009-2019.
    PubMed     Abstract available
    
    
    
90. JUNG BC, Woo SH, Kim SH, Kim YS, et al
    Parkin Enhances Gefitinib-induced Anoikis in HeLa Cervical Cancer Cells.
    Anticancer Res. 2024;44:1853-1862.
    PubMed     Abstract available
    
    
    
91. WILLSON CM, Lequio M, Zhu Z, Wakefield MR, et al
    The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells.
    Anticancer Res. 2024;44:1807-1815.
    PubMed     Abstract available
    
    
    
92. KUM SJ, Jung YY, Kim HS
    Comparison of Clinicopathological and Prognostic Characteristics Between Minimal Deviation Adenocarcinoma and Gastric-type Endocervical Adenocarcinoma.
    Anticancer Res. 2024;44:2193-2204.
    PubMed     Abstract available
    
    
    
93. MOREA A, Saravi S, Sisu C, Hall M, et al
    Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model.
    Anticancer Res. 2024;44:1817-1827.
    PubMed     Abstract available
    
    
    April 2024
94. XU X, Wang Q, Shen L, Shen Y, et al
    Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness.
    Anticancer Res. 2024;44:1399-1407.
    PubMed     Abstract available
    
    
    
95. TSENG CC, Ku MH, Wu YC, Huang WL, et al
    Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer.
    Anticancer Res. 2024;44:1353-1364.
    PubMed     Abstract available
    
    
    
96. CHU J, Lee SH, DO SI, Kim HS, et al
    Clinicopathological Significance of Nucleosome Remodeling and Deacetylase Complex Expression in Endometrial Carcinoma.
    Anticancer Res. 2024;44:1739-1750.
    PubMed     Abstract available
    
    
    
97. AOSHIKA T, Noda SE, Abe T, Kumazaki YU, et al
    Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer.
    Anticancer Res. 2024;44:1583-1589.
    PubMed     Abstract available
    
    
    
98. WANG X, Li C, Lou L, Zhu H, et al
    Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:1465-1473.
    PubMed     Abstract available
    
    
    March 2024
99. KIM JS, Shin MJ, Lee SY, Choi SM, et al
    BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells.
    Anticancer Res. 2024;44:1131-1142.
    PubMed     Abstract available
    
    
    October 2023
100. SAILLANT A, Rasclard M, Gaume JB, Souchaud O, et al
     A Case of Anti-3-hydroxy-3-methylglutaryl-coenzyme A Reductase Myopathy Associated With Advanced Cervical Carcinoma.
     Anticancer Res. 2023;43:4723-4727.
     PubMed     Abstract available
     
     
     
101. LIAKOU C, Pandraklakis A, LA Russa MC, Turnbull H, et al
     Interval Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Ovarian Cancer: Report of a Single-center Experience.
     Anticancer Res. 2023;43:4593-4599.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum